Michael W. Nall, BioClinica's CEO & President and a director of the company, recently acquired 13,348 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on February 29, 2016. Nall now owns 39,634 shares of the company. Nall operates out of San Diego, CA. Some additional info was provided as follows:
Shares were issued upon the vesting of a restricted stock unit pursuant to the achievement of performance criteria.
25% of the shares subject to the option shall vest on the first annual anniversary of the Vesting Commencement Date (2/29/16) with the balance vesting in equal monthly installments thereafter until fully vested on February 29, 2020.
The above i nformation was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever BioClinica makes a similar move, sign up!
Other recent filings from the company include the following:
On February - Feb. 12, 2018
Sabby Healthcare Master Fund, Ltd. just issued a filing suggesting it has sold all of its Biocept - Feb. 1, 2018
On January - Jan. 30, 2018
Biocept just filed a prospectus, suggesting it plans to soon issue some securities - Jan. 26, 2018
Registration adding securities to prior Form S-1 registration [Rule 462(b)] - Jan. 26, 2018